Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Randomized, double-blinded phase III trial evaluating Donanemab vs Placebo (treatment) in patients with Alzheimer's Disease (early)
Primary outcome measures:
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)
The author’s conclusion was: Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population.
Sims et al. 2023 JAMA 330: 512-527
…